[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618841":3},{"organization":4,"outcomesModule":7,"designInfo":73,"detailedDescription":79,"studyPopulation":16,"armGroups":80,"interventions":92,"overallOfficials":101,"centralContacts":105,"locations":111,"responsibleParty":125,"collaborators":16,"id":128,"slug":16,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":129,"sex":135,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":16,"studyType":141,"phases":142,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":113,"whyStopped":16,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},{"fullName":5,"class":6},"China-Japan Friendship Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":60},[9],{"measure":10,"description":11,"timeFrame":12},"the Percentage of weight loss","Through study completion, an average of 1 year, the investigators will observe the Percentage of weight loss.","1 year",[14,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58],{"measure":15,"description":16,"timeFrame":17},"Gender",null,"Immediately postoperatively (Day 0), and at 1, 3, 6, and 12 months postoperatively.",{"measure":19,"description":16,"timeFrame":17},"Ethnicity",{"measure":21,"description":16,"timeFrame":17},"Height in meters",{"measure":23,"description":16,"timeFrame":17},"Weight in kilograms",{"measure":25,"description":16,"timeFrame":17},"Waist circumference in centimeters",{"measure":27,"description":16,"timeFrame":17},"Hip circumference in centimeters",{"measure":29,"description":16,"timeFrame":17},"Blood pressure",{"measure":31,"description":16,"timeFrame":17},"Serum creatinine",{"measure":33,"description":16,"timeFrame":17},"Glomerular filtration rate",{"measure":35,"description":16,"timeFrame":17},"Fasting blood glucose",{"measure":37,"description":16,"timeFrame":17},"Average blood glucose from continuous glucose monitoring",{"measure":39,"description":16,"timeFrame":17},"Postprandial 2-hour blood glucose",{"measure":41,"description":16,"timeFrame":17},"HbA1c",{"measure":43,"description":16,"timeFrame":17},"Urinary microalbumin and other Urinalysis indexes",{"measure":45,"description":16,"timeFrame":17},"Total cholesterol",{"measure":47,"description":16,"timeFrame":17},"Low-Density Lipoprotein(LDL)",{"measure":49,"description":16,"timeFrame":17},"High-Density Lipoprotein(HDL)",{"measure":51,"description":16,"timeFrame":17},"Triglycerides",{"measure":53,"description":16,"timeFrame":17},"Alanine Aminotransferase(ALT)",{"measure":55,"description":16,"timeFrame":17},"Aspartate Aminotransferase(AST)",{"measure":57,"description":16,"timeFrame":17},"urine microalbumin-to-creatinine ratio (ACR)",{"measure":59,"description":16,"timeFrame":17},"uric acid(UA)",[61,63,65,67,69,71],{"measure":62,"description":16,"timeFrame":17},"body fat percentage(BFP)",{"measure":64,"description":16,"timeFrame":17},"Visceral fat area",{"measure":66,"description":16,"timeFrame":17},"Muscle mass in kilograms",{"measure":68,"description":16,"timeFrame":17},"Body fat percentage",{"measure":70,"description":16,"timeFrame":17},"lean body mass (LBM)",{"measure":72,"description":16,"timeFrame":17},"lean body mass percentage (LBMP)",{"allocation":74,"interventionModel":75,"interventionModelDescription":16,"primaryPurpose":76,"observationalModel":16,"timePerspective":16,"maskingInfo":77},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":78,"maskingDescription":16,"whoMasked":16},"NONE","\"bariatric surgery is guideline-recommended as an effective obesity treatment. Substantial evidence demonstrates its ability to significantly reduce weight, improve comorbidities like type 2 diabetes (T2DM) and dyslipidemia, and lower cardiovascular risk. However, the significant heterogeneity and complex comorbidity profiles among obese patients challenge long-term effective management with single therapeutic approaches. While currently the most effective weight-loss intervention, bariatric surgery requires attention to issues such as postoperative weight regain and metabolic deterioration.\n\nIn parallel, Glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated significant efficacy in obesity management. Agents like semaglutide promote weight loss and metabolic improvement through mechanisms including insulin secretion promotion, appetite suppression, delayed gastric emptying, and enhanced satiety.\n\nGiven the distinct advantages of both bariatric surgery and GLP-1RA therapy in weight and metabolic control, this study will combine these modalities into a comprehensive treatment strategy. The investigators will compare the long-term safety and effectiveness of different combination regimens for weight management and metabolic improvement in patients with severe obesity.\"",[81,87],{"label":82,"type":83,"description":84,"interventionNames":85},"BS-GLP group","EXPERIMENTAL","Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: Semaglutide. Dosage:The starting dose was 0.25 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 2.4 mg per week.\n\nFrequency: Once per week. Duration: The treatment continued until the completion of the 6-month postoperative period.",[86],"Combination Product: BS-GLP group",{"label":88,"type":6,"description":89,"interventionNames":90},"BS group","Names for Surgery: Laparoscopic Sleeve Gastrectomy. Names for drugs: N\u002FA. Observation Group: Received only basic nutritional recommendation interventions after surgery.",[91],"Procedure: BS group",[93,97],{"type":94,"name":82,"description":95,"armGroupLabels":96,"otherNames":16},"COMBINATION_PRODUCT","1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal\u002Fday). From 30 to 90 days post-surgery, a low-energy diet (400 kcal\u002Fday) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal\u002Fday for men and 1,200 kcal\u002Fday for women).\n2. In addition to laparoscopic sleeve gastrectomy and postoperative basic nutritional counseling,the intervention group received subcutaneous semaglutide injections from 1 to 6 months postoperatively.The specific protocol was as follows:In the intervention group, semaglutide treatment was initiated at 1 month after LSG. The starting dose was 0.25 mg per week and was subsequently titrated up based on individual patient response to a maximum maintenance dose of 2.4 mg per week. The treatment continued until the completion of the 6-month postoperative period.",[82],{"type":98,"name":88,"description":99,"armGroupLabels":100,"otherNames":16},"PROCEDURE","1. Basic Treatment Measures Within 0-30 days after sleeve gastrectomy, all patients received very low-calorie enteral nutrition powder (100 kcal\u002Fday). From 30 to 90 days post-surgery, a low-energy diet (400 kcal\u002Fday) was provided. Beyond 90 days post-surgery, a calorie-restricted diet was implemented (1,500 kcal\u002Fday for men and 1,200 kcal\u002Fday for women).\n2. Observation Group: Received only basic nutritional recommendation interventions after surgery.",[88],[102],{"name":103,"affiliation":5,"role":104},"Hua Meng, Ph.D","PRINCIPAL_INVESTIGATOR",[106],{"name":107,"role":108,"phone":109,"phoneExt":16,"email":110},"Yishan Huang, Ph.D","CONTACT","18810621201","bucmyishan@163.com",[112],{"facility":5,"status":113,"city":114,"state":16,"zip":16,"country":115,"countryCode":116,"cosmosGeoPoint":117,"geoPoint":122,"contacts":123},"RECRUITING","Beijing","China","CN",{"type":118,"coordinates":119},"Point",[120,121],116.39723,39.9075,{"lat":121,"lon":120},[124],{"name":107,"role":108,"phone":109,"phoneExt":16,"email":110},{"type":104,"investigatorFullName":126,"investigatorTitle":127,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"Hua Meng","Prof.","100618841",false,"NCT07336862","Bariatric Surgery Combined With GLP-1 Receptor Agonists Study","The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Severe Obesity: A Prospective, Multicenter Cohort Study","BS-GLP","Inclusion Criteria:\n\n1. Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG)\n2. obesity:BMI ≥35 kg\u002Fm²\n3. Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria\n4. Age range: 18-60 years (inclusive)\n5. Informed consent: Willing participation with documented consent\n\nExclusion Criteria:\n\n1. Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively\n2. Prior bariatric surgery: History of any metabolic\u002Fbariatric surgical procedure\n3. Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak)\n4. Non-indicated candidates: Patients not meeting standard bariatric surgery indications\n5. Significant comorbidities:\n\n   * Advanced hepatic\u002Frenal dysfunction (Child-Pugh C or eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n   * Active malignancy (except non-melanoma skin cancers)\n   * Autoimmune disorders requiring immunosuppression\n   * Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression)","ALL","18 Years","60 Years",{"count":139,"type":140},200,"ESTIMATED","INTERVENTIONAL",[143,144],"PHASE1","PHASE2","Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.",[147],"Obesity",[149,150,151],"obesity","Glucagon-Like Peptide-1 Receptor Agonists","Bariatric Surgery","2026-04-20",{"date":154,"type":155},"2026-04-23","ACTUAL",{"date":157,"type":155},"2024-01-01",{"date":159,"type":140},"2027-12",{"name":5,"class":6},1]